2 weeks Ago By Defense World Staff
Commonwealth Equity Services LLC reduced its position in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The fund owned 76,397 shares of the biotechnology company’s stock after selling 14,924 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Pacific Biosciences of California were worth $140,000 at the end of the most recent reporting period. A number of other large investors have also made changes to their positions in PACB.
Charles Schwab Investment Management Inc. grew its stake in Pacific Biosciences of California by 4.2% during the 3rd quarter.
Charles Schwab Investment Management Inc. now owns 2,040,303 shares of the biotechnology company’s stock worth $3,469,000 after buying an additional 82,807 shares during the last quarter. FMR LLC boosted its holdings in Pacific Biosciences of California by 641.
3% in the third quarter. FMR LLC now owns 408,151 shares of the biotechnology company’s stock worth $694,000 after acquiring an additional 353,092 shares in the last quarter. Centiva Capital LP purchased a new stake in shares of Pacific Biosciences of California during the third quarter worth about $40,000.
State Street Corp grew its stake in shares of Pacific Biosciences of California by 5.7% during the third quarter. State Street Corp now owns 6,276,156 shares of the biotechnology company’s stock worth $10,669,000 after acquiring an additional 340,766 shares during the last quarter.
Finally, XTX Topco Ltd acquired a new position in shares of Pacific Biosciences of California during the third quarter valued at about $97,000. Analyst Upgrades and Downgrades Several analysts have weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of Pacific Biosciences of California from $1.
75 to $1.50 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Piper Sandler reissued a “neutral” rating and set a $2.
00 price objective (down from $2.50) on shares of Pacific Biosciences of California in a report on Thursday, February 20th. Scotiabank reduced their target price on Pacific Biosciences of California from $6.
00 to $2.00 and set a “sector outperform” rating for the company in a research note on Tuesday, March 25th. Canaccord Genuity Group reiterated a “buy” rating and set a $3.
00 price target on shares of Pacific Biosciences of California in a research note on Thursday. Finally, StockNews.com raised Pacific Biosciences of California to a “sell” rating in a report on Tuesday, February 25th.
One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Pacific Biosciences of California presently has a consensus rating of “Hold” and a consensus target price of $2.46.
Pacific Biosciences of California Stock Down 4.8 % Shares of PACB stock opened at $1.38 on Friday.
Pacific Biosciences of California, Inc. has a twelve month low of $1.08 and a twelve month high of $3.
47. The stock has a market cap of $411.04 million, a P/E ratio of -0.
84 and a beta of 2.04. The stock has a 50 day moving average of $1.
39 and a 200 day moving average of $1.72. The company has a current ratio of 9.
74, a quick ratio of 8.64 and a debt-to-equity ratio of 1.97.
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) last posted its earnings results on Thursday, February 13th. The biotechnology company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.
20). Pacific Biosciences of California had a negative net margin of 200.40% and a negative return on equity of 42.
89%. The firm had revenue of $39.22 million during the quarter, compared to analyst estimates of $39.
20 million. During the same period in the previous year, the firm earned ($0.27) EPS.
As a group, sell-side analysts expect that Pacific Biosciences of California, Inc. will post -0.72 EPS for the current year.
Insiders Place Their Bets In other news, insider Michele Farmer sold 24,349 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $1.88, for a total transaction of $45,776.
12. Following the sale, the insider now directly owns 187,592 shares in the company, valued at $352,672.96.
This trade represents a 11.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website .
Insiders own 2.40% of the company’s stock. About Pacific Biosciences of California ( Free Report ) Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems.
The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. Read More Five stocks we like better than Pacific Biosciences of California Stock Average Calculator Joby Aviation: Operational Momentum vs. Market Sentiment Investing In Preferred Stock vs.
Common Stock Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline Unveiling The Power Of VWAP: A Key Indicator For Traders Carvana: Can Turnaround Strength Outdrive Market Headwinds? Want to see what other hedge funds are holding PACB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ).
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter ..
